A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter Phase 2 Induction Study With Long-Term Extension to Evaluate the Clinical Activity and Safety of Oral NX-13 in Participants w/ Moderate to Severe Ulcerative Colitis

Protocol No
GI-LANDOS-NX-13-201
Phase
II
Summary

This project is being done to find out more about NX-13, an investigational drug, in people with ulcerative colitis. We want to determine if it reduces the symptoms of ulcerative colitis, and whether it causes any problems (side effects).

Description
Oral NX-13 in Moderate to Severe Ulcerative Colitis
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Categories
Digestive System, Other
ClinicalTrials.gov
go to website